Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 5/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 5/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 5/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.42 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.38 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29947549 | 1.00 | ADRA2A (0.42) | ADRA2AADRA2BADRA2CADRA1AADRA1D | |
| SCHEMBL2607435 | 0.84 | ADRA2A (0.44) | ADRA2AADRA2BADRA2CADRA1AADRA1D | |
| SCHEMBL29875062 | 0.84 | ADRA2A (0.44) | ADRA2AADRA2BADRA2CADRA1AADRA1D | |
| SCHEMBL28005982 | 0.81 | CYP1A2 (0.44) | ADRA2AADRA2BADRA2CADRA1AADRA1D | |
| SCHEMBL30238657 | 0.81 | PRKCZ (0.43) | ADRA2AADRA2BADRA2CADRA1AADRA1D | |
| SCHEMBL13509959 | 0.81 | ADRA2A (0.41) | ADRA2AADRA2BADRA2CADRA1AADRA1D | |
| SCHEMBL28454494 | 0.81 | PRKCZ (0.43) | ADRA2AADRA2BADRA2CADRA1AADRA1D | |
| SCHEMBL20824746 | 0.81 | PRKCZ (0.43) | ADRA2AADRA2BADRA2CADRA1AADRA1D | |
| SCHEMBL31370410 | 0.79 | AKR1B1 (0.43) | ADRA2AADRA2BADRA2CADRA1AADRA1D | |
| SCHEMBL18400234 | 0.78 | TSHR (0.44) | ADRA2AADRA2BADRA2CADRA1AADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117120439-A | FGFR3 inhibitor compounds | 伊莱利利公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-102245593-A | Isoquinolinone derivatives | ASTRAZENECA AB | 2011-11-16 | — | — | CN | disclosed |
| EP-1392280-A4 | ARYLSULFONAMIDE ETHERS, AND METHODS OF USE THEREOF | WARNER LAMBERT CO (US) | 2005-11-30 | — | — | EP | disclosed |
| US-6875765-B2 | Arylsulfonamide ethers, and methods of use thereof | WARNER-LAMBERT COMPANY (US) | 2005-04-05 | — | — | US | disclosed |
| EP-1392280-A2 | ARYLSULFONAMIDE ETHERS, AND METHODS OF USE THEREOF | Abbott GmbH & Co. KG (DE) | 2004-03-03 | — | — | EP | disclosed |
| US-20030096826-A1 | Arylsulfonamide ethers, and methods of use thereof | WARNER-LAMBERT COMPANY | 2003-05-22 | — | — | US | disclosed |
| WO-2002089749-A2 | ARYLSULFONAMIDE ETHERS, AND METHODS OF USE THEREOF | ABBOTT GMBH & CO.KG (DE) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096826-A1 | Arylsulfonamide ethers, and methods of use thereof | CASP1, IRAK1, STS | ADRA2A 3503/4885ADRA2B 3361/4885ADRA2C 3463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.